USPTO serial 79126292
ENTEROME
Reviewed by CopyMark Law Group
Reg. 4561761Status 706Registered
- Filing date
- Status date
- Registration date
- Jul 8, 2014
- Examiner
- TANNER, MICHAEL R
- Law office
- Historical data usage
What this means
This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.
Need help with ENTEROME?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Thomas M. Palisi
THOMAS M. PALISI Lerner David LLP20 Commerce DriveCranford, NJ 07016United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | [ Chemical and biochemical substances used for the manufacture and preservation of foodstuffs, of pharmaceutical, cosmetic and veterinary products, namely, probiotic bacteria and probiotic bacterial cultures for use in the manufacture of food products and pharmaceutical preparations, prebiotic bacteria and prebiotic bacterial cultures for use in the manufacture of food products and pharmaceutical preparations, enzymes for use in the manufacture of food products and pharmaceutical preparations ] | SECTION 71 - CANCELLED | — |
| 003 | [ Cosmetic products, namely, cosmetic creams ] | SECTION 71 - CANCELLED | — |
| 005 | Pharmaceutical and medicinal products for human and veterinary use, namely, pharmaceutical preparations for treating metabolic disorders, immunological disorders, cancers, central nervous systems disorders, gastroenterological disorders, infectious diseases, diarrhea, constipation and irritable bowel syndrome; veterinary products, namely, anti-infective products for veterinary use, veterinary pharmaceutical preparations for treatment of metabolic disorders, immunological disorders, cancers, central nervous systems disorders, gastroenterological disorders, infectious diseases and diarrhea; medicinal products for human and veterinary use, namely, nutritional supplements containing probiotic compositions; sanitary products for use in medicine, namely, sanitary sterilizing preparations, disinfectants for sanitary purposes, sanitary preparations for medical use; dietetic food and substances for medical use in the nature of meal replacement products and prepackaged meal plans, namely, nutritional meal replacement bars adapted for medical use for treating metabolic disorders, immunological disorders, central nervous systems disorders, gastroenterological disorders, infectious diseases, diarrhea, constipation and irritable bowel syndrome, prepared, prepackaged entrees for medical use for treating metabolic disorders, immunological disorders, central nervous systems disorders, gastroenterological disorders, infectious diseases, diarrhea, constipation and irritable bowel syndrome, prepared, prepackaged snack foods for medical use for treating metabolic disorders, immunological disorders, central nervous systems disorders, gastroenterological disorders, infectious diseases, diarrhea, constipation and irritable bowel syndrome, prepared, prepackaged yogurts for medical use for treating metabolic disorders, immunological disorders, central nervous systems disorders, gastroenterological disorders, infectious diseases, diarrhea, constipation and irritable bowel syndrome, prepared, prepackaged desserts for medical use for treating metabolic disorders, immunological disorders, central nervous systems disorders, gastroenterological disorders, infectious diseases, diarrhea, constipation and irritable bowel syndrome; nutritional supplements for medical use; food additives for medical use, namely, dietary fiber for treating metabolic disorders, gastroenterological disorders, diarrhea, constipation and irritable bowel syndrome; nutritional food additives for medical purposes in the nature of natural food extracts derived from fish, meat, vegetables, microorganisms and crops | ACTIVE | — |
| 042 | Human pharmaceutical research; research services provided by a pharmaceutical laboratory, namely, providing medical research testing services in the field of metabolic disorders, immunological disorders, central nervous systems disorders, gastroenterological disorders, infectious diseases, diarrhea, constipation, and irritable bowel syndrome; Providing medical and scientific research information in the field of metabolic disorders, immunological disorders, central nervous systems disorders, gastroenterological disorders, infectious diseases, diarrhea, constipation, and irritable bowel syndrome; providing medical and scientific research information in the field of pharmaceutical and clinical trials; scientific laboratory services, genetic testing of laboratory animals for pharmaceutical research purposes; biological research in the fields of microbiology and chemistry | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by ENTEROME
- Other trademarks owned by ENTEROME
- Other trademarks owned by ENTEROME
- Other trademarks in Class 001
- Other trademarks in Class 003
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named ENTEROME
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 15, 2026 | INNA | INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE | — |
| Dec 22, 2025 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Apr 22, 2025 | NA71 | NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED | — |
| Apr 22, 2025 | 71AG | REGISTERED-SEC.71 ACCEPTED | — |
| Apr 21, 2025 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Dec 9, 2024 | ES71 | TEAS SECTION 71 RECEIVED | — |
| Jul 8, 2023 | REM4 | COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED | — |
| Jan 26, 2023 | RNWL | INTERNATIONAL REGISTRATION RENEWED | — |
| Dec 12, 2021 | INNP | PARTIAL INVALIDATION PROCESSED BY THE IB | — |
| Nov 4, 2021 | INPS | PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Nov 4, 2021 | INPC | INVALIDATION PROCESSED | — |
| Oct 10, 2021 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Feb 10, 2021 | NA75 | NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED | — |
| Feb 10, 2021 | C75P | REGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK. | — |
| Feb 10, 2021 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Dec 29, 2020 | ES75 | TEAS SECTION 71 & 15 RECEIVED | — |
| Jan 23, 2015 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Dec 4, 2014 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Dec 4, 2014 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Oct 8, 2014 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jul 8, 2014 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 30, 2014 | ETOP | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | — |
| Feb 12, 2014 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Jan 14, 2014 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 11, 2014 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Dec 25, 2013 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Dec 25, 2013 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Dec 25, 2013 | NPUB | NOTICE OF PUBLICATION | — |
| Dec 6, 2013 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Dec 2, 2013 | ALIE | ASSIGNED TO LIE | — |
| Nov 7, 2013 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 22, 2013 | CNEA | EXAMINERS AMENDMENT MAILED | — |
| Oct 22, 2013 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Oct 22, 2013 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| May 15, 2013 | RFNP | REFUSAL PROCESSED BY IB | — |
| Apr 22, 2013 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Apr 22, 2013 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Apr 20, 2013 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Apr 19, 2013 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 17, 2013 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 15, 2013 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Mar 11, 2013 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 7, 2013 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |